Clinical trial · Interventional
Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant
Phase II Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant
NCT01019577CI-TRIAL-00025684completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the response rates for Ixabepilone (BMS-247550) in subjects with metastatic breast cancer previously treated with an anthracycline and who are taxane resistant.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ixabepilone | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Ixabepilone
- interventionNames
- Drug: Ixabepilone
Primary outcomes (1)
- measure
- To assess the tumor response using RECIST Criteria to determine the best overall response and response rate
- timeFrame
- For a maximum of 9 3-week cycles or until unacceptable toxicity
Secondary outcomes (3)
- measure
- To evaluate safety of BMS-247550 (AEs, SAEs, Deaths, treatment related AEs) using CTC Criteria
- timeFrame
- Every cycle
- measure
- To evaluate the duration of achieved responses
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Women aged 20 years or older * Patients with metastatic breast cancer whose primary lesion was definitely diagnosed to be breast by histological or cellular examination Exclusion Criteria: * Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≥ 2
References
Publications (0)
Data not yet available
No reference posted for this study.